Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15986821 | 1.00 | HDAC1 (0.66) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL25659873 | 1.00 | HDAC1 (0.66) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL18822849 | 1.00 | HDAC1 (0.66) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL31045861 | 0.86 | GRM1 (0.61) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL30767297 | 0.86 | HDAC1 (0.60) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL20141579 | 0.86 | GRM1 (0.61) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL18149853 | 0.86 | HDAC1 (0.60) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL18149851 | 0.86 | HDAC1 (0.60) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL31552986 | 0.86 | HDAC1 (0.60) | HDAC1MAP4K4GPR119HDAC2HDAC3 | |
| SCHEMBL16026429 | 0.85 | HDAC1 (0.67) | HDAC1MAP4K4GPR119HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023092098-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | HDAC1 222/4885MAP4K4 3122/4885GPR119 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.